Progyny (NASDAQ:PGNY – Get Rating) issued its quarterly earnings data on Thursday. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $0.04, Briefing.com reports. Progyny had a net margin of 7.39% and a return on equity of 18.11%. The firm had revenue of $195.00 million for the quarter, compared to analyst estimates of $190.51 million. During the same quarter in the previous year, the business posted $0.19 EPS. The firm's revenue was up 51.5% compared to the same quarter last year.
Progyny Price Performance
Shares of PGNY stock opened at $41.15 on Friday. Progyny has a 12 month low of $25.67 and a 12 month high of $68.32. The firm has a market capitalization of $3.78 billion, a P/E ratio of 89.46, a P/E/G ratio of 21.71 and a beta of 1.85. The company's fifty day moving average price is $30.23 and its two-hundred day moving average price is $37.32.
Insiders Place Their Bets
In other Progyny news, Chairman David J. Schlanger sold 1,452 shares of the business's stock in a transaction on Monday, June 27th. The shares were sold at an average price of $31.21, for a total value of $45,316.92. Following the transaction, the chairman now owns 82,548 shares in the company, valued at approximately $2,576,323.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Chairman David J. Schlanger sold 1,452 shares of the company's stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $31.21, for a total value of $45,316.92. Following the sale, the chairman now owns 82,548 shares in the company, valued at approximately $2,576,323.08. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Norman Payson sold 6,618 shares of the company's stock in a transaction dated Wednesday, May 11th. The shares were sold at an average price of $33.45, for a total transaction of $221,372.10. Following the completion of the sale, the director now owns 490,828 shares in the company, valued at approximately $16,418,196.60. The disclosure for this sale can be found here. Insiders have sold 41,240 shares of company stock worth $1,291,601 in the last quarter. 14.00% of the stock is owned by corporate insiders.
在Progyny的其他消息中，董事长David J.Schlanger在6月27日星期一的一次交易中出售了1,452股该公司的股票。这些股票的平均价格为31.21美元，总价值为45316.92美元。交易完成后，董事长现在拥有该公司82,548股，价值约2,576,323.08美元。这笔交易是在提交给美国证券交易委员会(Securities&Exchange Commission)的一份文件中披露的，可以通过这个链接访问。在其他新闻方面，董事长大卫·J·施兰格在一笔日期为6月27日星期一的交易中出售了1,452股公司股票。这些股票的平均价格为31.21美元，总价值为45316.92美元。出售后，董事长现在拥有该公司82,548股，价值约2,576,323.08美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，可以通过美国证券交易委员会网站访问该文件。此外，在一笔日期为5月11日(星期三)的交易中，董事诺曼·佩森出售了6618股该公司股票。这些股票的平均价格为33.45美元，总成交额为221,372.10美元。出售完成后，董事现在拥有该公司490,828股，价值约16,418,196.60美元。此次拍卖的披露信息可在此处找到。上个季度，内部人士出售了41,240股公司股票，价值1,291,601美元。14.00%的股份由企业内部人士持有。
Institutional Investors Weigh In On Progyny
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
- Get a free copy of the StockNews.com research report on Progyny (PGNY)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- 克罗诺斯集团(Cronos Group Inc.)营收上升，是时候收购了吗？
- Beyond Meat不是没有希望，而且它很便宜
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.